BNTC - Company ID 0001808898
The table below shows Benitec Biopharma Inc.'s income statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | - | $0.00 | $0.00 |
| Cost of revenue | - | - | - | - | - | - |
| Gross profit | - | - | - | - | - | - |
| R&D | $6.30M | $5.83M | $3.37M | $2.87M | $6.50M | $5.38M |
Benitec Biopharma Inc. reported annual revenue of $0.00 for fiscal year 2024. That is down 100.0% from $75.00K in fiscal 2023. Over the 6 fiscal years shown, annual revenue declined from $12.20M (FY 2019) to $0.00. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| SG&A |
| $7.28M |
| $7.54M |
| $6.43M |
| $6.97M |
| $8.84M |
| $5.42M |
| Operating income | -$13.58M | -$13.38M | -$9.80M | -$9.83M | -$15.34M | -$10.80M |
| Income tax | - | - | - | - | - | - |
| Net income | -$11.94M | -$11.84M | -$8.96M | -$8.80M | -$14.50M | -$9.55M |
| EPS (diluted) | -$0.24 | -$0.26 | -$0.22 | -$0.21 | -$0.38 | -$0.26 |